Efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime®) vs. Gonal-f® in women undergoing ovarian stimulation for IVF: A randomized, multicenter, evaluator-blinded, non-inferiority study

Abstract

Objective: We compared the efficacy, safety, and immunogenicity of a biosimilar recombinant human folliclestimulating hormone (Folitime ® ) with Gonal-f ® in women undergoing ovarian stimulation for in-vitro fertilization.Methods: This randomized (1:1), multicenter, assessor-blinded, non-inferiority, parallel-group, controlled study conducted at four infertility clinics in Argentina included infertile normogonadotropic women with ages below 39 years, with menstrual cycles of 25/35 days and a body mass index of 18-32 kg/m2 undergoing assisted reproductive technology therapy. During a 5-day fixeddose phase, the women received 225 IU/day of Folitime ® (n=49) or Gonal-f ® (n=44), followed by a dose-adaptation phase up to a maximum of 450 IU/day. The non-inferiority margin for oocyte retrieval was estimated at -4 oocytes (one-sided test). Immunogenicity was investigated on days 9 and 84, following the start of treatment.Results: The mean number of oocytes retrieved was 12.6 (SD 7.4) in the Folitime ® group and 13.4 (SD 6.9) in the Gonal-f ® group (per protocol analysis, 95% confidence interval = -3.82; 2.33), within the non-inferiority margin. Pregnancy rate at week 10 was 24.4% among subjects treated with Folitime ® and 19.5% for subjects treated with Gonal-f ® . One serious adverse drug reaction-late mild ovarian hyper stimulation syndrome and deep venous thrombosis in the left deep jugular vein-occurred in a subject treated with Folitime ® . None of the subjects developed antibodies against the study drugs. There were no unexpected safety findings.Conclusions: Folitime ® is non-inferior to Gonal-f ® , with no differences in the safety profile and has been approved as a biosimilar in Argentina.

Correlation of Insulin Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein with LH, FSH and Testosterone in Iraqi Children with Growth Hormone Deficiency

“…Using the quantitative sandwich immunoassay method, the amount of insulinlike growth factor binding protein is determined, concentration of follicular stimulating hormone and luteinizing hormone. The hormone testosterone was measured using the competitive binding approach, which produces a yellow product that corresponds to the hormone's concentration as determined by the standard curve [22,23].…”